NCT04885712View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or 30mg Add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

PHASE3CompletedINTERVENTIONAL
Enrollment

378

Participants

Timeline

Start Date

May 28, 2021

Primary Completion Date

September 19, 2022

Study Completion Date

March 10, 2023

Conditions
Type2 Diabetes
Interventions
DRUG

Metformin≥1000mg

Subjects take the investigational products once a day for 24 weeks.

DRUG

Pioglitazone 15mg

Subjects take the investigational products once a day for 24 weeks.

DRUG

Pioglitazone 30 mg

Subjects take the investigational products once a day for 24 weeks.

DRUG

Pioglitazone 15mg Placebo

Subjects take the investigational products once a day for 24 weeks.

DRUG

Pioglitazone 30mg Placebo

Subjects take the investigational products once a day for 24 weeks.

DRUG

Dapagliflozin 10mg

Subjects take the investigational products once a day for 24 weeks.

Trial Locations (1)

Unknown

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Boryung Pharmaceutical Co., Ltd

INDUSTRY